Claessens Jade, Packlé Loren, Oosterbos Hanne, Smeets Elke, Geens Jelena, Gielen Jens, Van Genechten Silke, Heuts Samuel, Maessen Jos G, Yilmaz Alaaddin
UHasselt-Hasselt University, Limburg Clinical Research Center, Hasselt, Belgium.
Department of Cardiothoracic Surgery, Jessa Hospital, Hasselt, Belgium.
Interdiscip Cardiovasc Thorac Surg. 2024 Sep 4;39(3). doi: 10.1093/icvts/ivae159.
Totally endoscopic coronary artery bypass grafting (TECAB) is a minimally invasive approach to achieve surgical revascularization through a minimally invasive approach. Still, data regarding non-robotic TECAB are limited. This report presents the results of a TECAB technique using long-shafted instruments, defined as Endo-CABG, from a single-centre experience in 1500 consecutive patients.
One thousand and five hundred patients underwent Endo-CABG between January 2016 and February 2023. Data were collected retrospectively, and patients were followed up for 1 year. The primary outcome of this study was major adverse cardiac and cerebrovascular events (MACCE)-free survival. Secondary efficacy outcomes were graft failure and mortality. Furthermore, we analysed factors influencing long-term freedom from MACCE and all-cause mortality.
The mean age was 68 [61-75] years, of which 193 (12.87%) were octogenarians. Multivessel disease was present in 1409 (93.93%) patients, and the mean EuroSCORE II was 1.64 [1.09-2.92] %. All patients underwent full arterial revascularization with bilateral internal mammary grafting in 88.47%. Graft failure occurred in 1.80% of cases after 1 year (n = 27). Thirty-day mortality was 1.73% (n = 26), 1-year survival was 94.7% (95% CI: 93.5-95.9%; n = 26) and 1-year MACCE-free survival was 91.7% (95% CI: 90.2-93.2%). Age, left ventricular ejection fraction, arterial hypertension and urgency were significantly associated with 1-year MACCE-free survival.
Endo-CABG appears to be a safe procedure, achieves surgical revascularization and provides good outcomes regarding graft failure and MACCE at 1 year, while age, left ventricular ejection fraction, arterial hypertension and urgency were associated with 1-year outcomes.
全胸腔镜冠状动脉旁路移植术(TECAB)是一种通过微创方法实现手术血运重建的微创术式。然而,关于非机器人辅助TECAB的数据有限。本报告介绍了一项在1500例连续患者中采用长柄器械(定义为Endo-CABG)进行TECAB技术的单中心经验结果。
2016年1月至2023年2月期间,1500例患者接受了Endo-CABG手术。数据进行回顾性收集,患者随访1年。本研究的主要结局是无主要不良心脑血管事件(MACCE)生存。次要疗效结局是移植物失败和死亡率。此外,我们分析了影响长期无MACCE和全因死亡率的因素。
平均年龄为68[61 - 75]岁,其中193例(12.87%)为80岁及以上患者。1409例(93.93%)患者存在多支血管病变,平均欧洲心脏手术风险评估系统(EuroSCORE)II评分为1.64[1.09 - 2.92]%。所有患者均接受了完全动脉血运重建术,88.47%的患者采用双侧胸廓内动脉移植。1年后移植物失败发生率为1.80%(n = 27)。30天死亡率为1.73%(n = 26),1年生存率为94.7%(95%CI:93.5 - 95.9%;n = 26),1年无MACCE生存率为91.7%(95%CI:90.2 - 93.2%)。年龄、左心室射血分数、动脉高血压和急诊情况与1年无MACCE生存率显著相关。
Endo-CABG似乎是一种安全的手术,可实现手术血运重建,并在1年时在移植物失败和MACCE方面提供良好结局,而年龄、左心室射血分数、动脉高血压和急诊情况与1年结局相关。